View Financial HealthXebra Brands 배당 및 자사주 매입배당 기준 점검 0/6Xebra Brands 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (CA$3.79m market cap, or US$2.71m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).공시 • Jan 22Xebra Brands Ltd. announced that it expects to receive CAD 0.15 million in fundingXebra Brands Ltd. announced a non-brokered private placement that it will issue up to 3,000,000 units of the Company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 150,000 on January 22, 2025. Each Unit will consist of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.10 per Warrant Share at any time for a period of twenty-four months following the closing of the Offering. It is expected that the closing of the Offering will be on or about January 30, 2025, or such other date or dates that company may determine. The offering is subject to the receipt of all regulatory approvals, including the approval of the Canadian Securities Exchange. Certain directors and officers of the Company are expected to participate in the Offering.New Risk • Jan 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Market cap is less than US$10m (CA$3.21m market cap, or US$2.24m).공시 • Jul 09Xebra Brands Successfully Completes First Manufacturing Run for Elements Brand Ahead of Growing Demand in MexicoXebra Brands Ltd. announced the successful completion of its first manufacturing run of its highly anticipated Elements line. This milestone represents a significant next step forward in Xebra Brands' commercialization efforts as the company prepares for initial distribution efforts in Mexico. The authorization for the importation, launch, and sale of the Elements Full Spectrum CBD Tinctures were granted to Elements Bioscience SAPI de C.V, a fully owned subsidiary of Xebra Brands Ltd, by Mexican regulatory authorities (COFEPRIS), and are expected to be sold in wellness and supplement stores, pharmacies and other retail channels which have accelerated their demand for new products.공시 • Apr 17Xebra Brands Ltd. Receives Second CBD Product Approval by COFEPRISXebra Brands Ltd. announced that it has received approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its second CBD product authorization to be sold in Mexico. This latest approval marks another milestone for Xebra Brands and highlights the Company's commitment to providing high-quality CBD products to consumers in Mexico. Building on the success of its first product approval in Mexico, Xebra Brands has obtained authorization for the transportation, launch, and sale of an additional 250mg Tincture, expanding its product offerings to meet the growing demand for premium CBD options in the region. Similar to its previously approved Tangerine Flavor CBD Tincture, this new product reflects Xebra's dedication to innovation, quality, and compliance within the CBD industry. Xebra Brands' 250mg Tincture is formulated with the same dedication to quality and purity as its previous offerings. Crafted with premium CBD extract, each batch of tincture undergoes thorough testing by third-party laboratories to ensure potency and consistency. This commitment to quality ensures that consumers in Mexico have access to trusted and reliable CBD products. With the approval of its second product by COFEPRIS, Xebra Brands reaffirms its position as a leader in the Mexican CBD industry. The company remains dedicated to meeting the evolving needs of consumers and providing natural wellness solutions that promote stress relief, relaxation, and overall well-being.공시 • Apr 05Xebra Brands Ltd. Submits Third Product Submission to Cofepris, Expanding Elements Brand Cbd LineupXebra Brands Ltd. announced the submission of its third product application for approval to COFEPRIS (Federal Commission for Protection Against Sanitary Risk) in Mexico for domestic production. This latest submission underscores Xebra's commitment to delivering high-quality CBD products to consumers across the country in a variety of formats. The newest addition to Xebra's Elements brand is a topical lotion meticulously crafted to provide targeted relief and nourishment for the skin, infused with premium CBD extract. Designed with precision and care, this topical lotion offers consumers a luxurious skincare experience backed by the trusted Elements brand. With the submission of the Elements Topical Lotion, Xebra now covers three major product categories in the Mexico CBD market, including topicals, tinctures, and capsules. The Company intends to continue applying for new product offerings to domestically produce products and expand into additional categories to meet the evolving needs of its consumers. Once approved by COFEPRIS, the Elements Topical Lotion will be available for purchase nationwide, providing consumers with a trusted, domestically produced solution for their skincare needs.공시 • Mar 08Xebra Brands Ltd. announced that it has received CAD 1 million in fundingOn March 7, 2024, Xebra Brands Ltd. closed the transaction. All of the units sold under the offering were purchased by David Ross Macias Diaz under a strategic investment agreement. Following the closing of the offering, David Ross Macias Diaz holds 18.04% and 30.56% of the common shares of the Company on a non-diluted basis and partially diluted basis, respectively. The offering is subject to the final acceptance of the CSE.공시 • Feb 03+ 1 more updateXebra Brands Ltd. Announces Management ChangesXebra Brands Ltd. announced a business transformation plan that will shift the Company's resources away from Canadian cannabis beverages to focus on the development and commercialization of the authorizations to manufacture cannabis products in Mexico. As part of the implementation of the Business Transformation Plan, newly appointed board member David Ross Macias Diaz has committed to an investment into the Company. Business Transformation Plan includes: Transforming the business strategy into a Mexico first model focused on generating revenues via the cannabis authorizations granted to Xebra in 2023 through partnership opportunities, listing of own products and possible M&A transactions of companies within Mexico; Scaling down the capital-intensive operations of the Company's Canadian Cannabis Beverages business; Appointing Rodrigo Gallardo as Interim-CEO to implement the Business Transformation Plan; Streamlining current corporate and operational staff to minimize cash expenditures; Realignment of current board seats from with eight (8) members to four (4) members; Revised Business Strategy. Under the Business Transformation Plan, the Company's core focus will be on commercializing the authorizations granted to Xebra an outright first-mover-advantage in Mexico, allowing Xebra and its partners to import and acquire cannabis seeds, cultivate and harvest cannabis, process and produce cannabis, and sell cannabis products both domestically and through export.Board Change • Nov 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Erick Ponce was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 21Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023.공시 • Feb 17Xebra Brands Ltd. announced that it expects to receive CAD 0.6 million in fundingXebra Brands Ltd. announced a non-brokered private placement of up to 8,000,000 units at a price of CAD 0.075 per unit for gross proceeds of up to CAD 600,000 on February 15, 2023. Each unit consists of one common share and one half of one warrant. Each whole warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 per share at any time within 18 months after closing. All securities to be issued in the transaction will be subject to a 4 month and one day hold period. The transaction is subject to receipt of all required regulatory and CSE approvals. The transaction is expected to close on or around March 1, 2023. The company may pay finders' fees in cash or securities, or a combination of both, as permitted by the policies of the CSE.Board Change • Feb 07Less than half of directors are independentFollowing Director Keith Dolo's arrival on 01 February 2023, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Feb 04Xebra Brands Ltd. Appoints Keith Dolo to the Board of DirectorsXebra Brands Ltd. announced that Mr. Keith Dolo has been appointed to Xebra's Board of Directors. Keith is a seasoned cannabis executive and was formerly the Founder and CEO Sproutly Canada one of Canada's early Licensed Producers. He is a partner with venture capital firms Greenbridge Capital and Nautilus Capital, as well the Co-Founder of Maverick Brands which is a growth agency & accelerator that invests in, supports, and scales high growth brands across many different industries including the Cannabis and beverage industries. Keith was previously a VP at Robert Half International for over a decade.공시 • Jan 27+ 1 more updateXebra Announces Management ChangesXebra Brands Ltd. announced board and management changes. Robert Giustra has resigned as Chairman and Director in order to focus on his mining ventures. Mr. Giustra will remain an advisor to Xebra. Mr. Giustra is the founder of Xebra Brands; under his leadership, Xebra obtained an irrevocable injunction by the Mexican Supreme Court and created Xebra's unique beverage brands and trademarks. Over the last year Mr. Giustra transitioned the incoming CEO, and oversaw the Canadian launch of Xebra's highly successful THC and CBN infused lemonade Vicious Citrus. Daniela Freitas, Corporate Secretary have also resigned with Mr. Giustra to focus on the mining sector; Rodrigo Gallardo, Xebra's President, has been appointed CFO and Corporate Secretary on an interim basis.공시 • Dec 21Xebra Brands Ltd. Announces District Court Orders Mexican FDA to Grant CannabisXebra Brands Ltd. announce, that further to its press release of December 8, 2022, a District Court judge has ruled in favor of Xebra Mexico. On December 8, 2022, Xebra announced that the Mexican Health Regulatory Agency, had formally notified Xebra's Mexican subsidiary, Desart MX, SA de CV, with a resolution in which it claimed to have complied with the Supreme Court mandate to grant Xebra cannabis authorizations. Xebra however indicated that in its opinion, and in the opinion of its legal advisors, the resolution issued by the COFEPRIS did not fulfill the mandate of the Supreme Court. A District Court judge has now reviewed the COFEPRIS resolution and ruled in favor of Xebra Mexico, outright rejecting its scope and language as materially insufficient and upholding Xebra's irrefutable legal rights granted by the Supreme Court. Thus, the judge ordered the COFEPRIS to issue the full and proper authorizations within 3 business days. Due to many Mexican government offices closing during the holiday season, Xebra anticipates the process of issuing the authorizations to continue into January 2023. Furthermore, since these cannabis authorizations are without legal precedent in Mexico, guidance on approximate timing cannot be relied upon, and additional delays can be reasonably expected. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation, processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.공시 • Nov 18Xebra Brands Ltd. Provides Update on the Issuance of its Mexican Cannabis AuthorizationsXebra Brands Ltd. provides an update on the issuance of its Mexican cannabis authorizations. Xebra previously announced that it expected the issuance of cannabis authorizations to its Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico") in October. The Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), has been officially ordered by the courts to grant the authorization. Since these are the first cannabis authorization in Mexico related to seed importation, cultivation, processing, and manufacturing; they are without legal precedent, hence the COFEPRIS has requested, and has been granted, extensions by the courts to issue the authorizations. The most recent extension expires in approximately two (2) weeks. Xebra and the COFEPRIS are working diligently with the aim of effecting the issuance of the authorizations as soon as possible. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation and processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Aug 25Xebra's Vicious Citrus Cannabis Infused Lemonade Now SellingXebra Brands Ltd. announced that its Vicious Citrus brand of cannabis-infused lemonades is now officially retailing in Canada and available for purchase in the province of Ontario, with more provinces to follow in the coming days and weeks. Vicious Citrus is a non-carbonated THC infused lemonade beverage, with a tangy citrus flavour and a 5:1 THC /CBN ratio. With the maximum amount of psychoactive cannabinoids allowed in any Canadian listed beverage, Vicious Citrus combines 10mg of THC with 2mg of CBN (Cannabinol) and is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America.Board Change • Aug 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jul 07Xebra Brands Ltd. Launches Vicious Citrus THC/CBN LemonadeXebra Brands Ltd. announced the successful completion of the first commercial production run of its Vicious Citrus cannabis infused lemonade. Availability is anticipated this summer in multiple provinces across Canada, including in Ontario, which has made an initial purchase order of 10,500 units for late July delivery; more than 1,100 retail cannabis store licences have been issued in Ontario, making it by far the most lucrative cannabis market in Canada. Xebra has engaged a national cannabis sales & marketing agency to introduce and support the growth of Vicious Citrus Lemonade to Canadian cannabis retailers. Xebra Launches Vicious Citrus THC/CBN Lemonade (CNW Group/Xebra Brands Ltd.) Xebra expects to launch additional Vicious Citrus cannabis infused beverages into the Canadian market later this year and into 2023. In addition, Xebra is evaluating opportunities to introduce Vicious Citrus andother Cannabis infused beverage brands into other countries.공시 • Jun 25Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 20+ 1 more updateXebra Brands Ltd. Appoints Jay Garnett as Chief Executive OfficerXebra Brands Ltd. announced that Mr. Jay Garnett has been appointed Chief Executive Officer. Mr. Garnett, is a serial entrepreneur and corporate executive with many years of success in founding and leading consumer-packaged-goods and beverage companies in Canada and the United States.공시 • Apr 13Xebra Brands Announces its Vicious Citrous Cannabis Infused LemonadXebra Brands Ltd. announced that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada. Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol). Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America.공시 • Apr 12Xebra Brands Ltd. announced that it has received CAD 1.8 million in fundingOn April 11, 2022, Xebra Brands Ltd. closed the transaction. The company has received total CAD 1,800,000 through issuance of 15,000,000 units at an issue price of CAD 0.12 per unit. The transaction is oversubscribed. An aggregate of 257,063 shares, 504,560 warrants and CAD 60,547 is paid in finder's fees. The securities issued in the Private Placement are subject to a hold period expiring on August 9, 2022.공시 • Apr 01Xebra Brands Ltd. Successfully Cultivates and Harvests First Cannabis Crop in the NetherlandsXebra Brands Ltd. announced that it has successfully cultivated and harvested its first cannabis crop in the Netherlands. Samples of the crop were collected by the Dutch government's Bureau of Medicinal Cannabis, March 25, 2022. The crop consisted of high THC ±22% cannabis flower, and flower with balanced THC ±6% and CBD± 8%. As 1 of only 5 companies to be selected by the Dutch government to participate in the medicinal cannabis cultivation pilot trial, Xebra is endeavoring to be awarded 1 of 2 licenses, providing government guaranteed revenues for each company of a minimum of approximately $80 million (€70.5 million), to supply all pharma-grade cannabis to be sold though pharmacies in the Netherlands. The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters. The deadline for the first crop was March 29, 2022 which has now been satisfied. The deadline for submission of the second crop is September 19, 2022, and March 6, 2023, for the third and final crop. A detailed business plan must also be provided to Dutch authorities by November 14, 2022. The announcement of provisional award decision by the Dutch government is scheduled for April 3, 2023, with commencement of a Framework Agreement for commercial operations planned for May 1, 2023. Cultivation in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks.공시 • Mar 04Xebra Brands Ltd. Readies for Launch of Its Unique and Pioneering Cannabis Infused Lemonade in CanadaXebra Brands Ltd. reported on its progress towards having its first cannabis beverage product, Vicious Citrus Lemonade available for sale in Canada. The Xebra team has been actively targeting the three major provinces of Alberta, British Columbia and Ontario with its differentiated product offering. Vicious Citrus Lemonade, combines 10mg of THC with 2mg of CBN (Cannabinol) per serving for an entourage experience that cannot be found in most cannabis products in Canada. To Xebra's knowledge, Vicious Citrus is one of only very few beverages in Canada containing CBN. CBN is a unique cannabinoid that is booming in interest across North America. Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have growing excitement about for its adult use effects and potential medicinal benefits. In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone human testing. The human testing was carried-out with the approval of Health Canada.공시 • Feb 26Xebra Brands Ltd. announced that it expects to receive CAD 1.2 million in fundingXebra Brands Ltd. announced a non-brokered private placement of up to 10,000,000 units at an issue price of CAD 0.12 per unit for gross proceeds of up to CAD 1,200,000 on February 25, 2022. Each unit is comprised of one common share, and a half warrant. Each full warrant entitles the holder, on exercise, to purchase one share at a price of CAD 0.25, for a period of 12 months from the date of issue. The company may pay finder's fees of 7% in cash or shares. The transaction is subject to approval from Canadian Securities Exchange.공시 • Nov 24Xebra Brands Ltd. announced that it has received CAD 1.34 million in fundingOn November 23, 2021, Xebra Brands Ltd. closed the transaction.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 XBRA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: XBRA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Xebra Brands 배당 수익률 vs 시장XBRA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (XBRA)n/a시장 하위 25% (CA)1.7%시장 상위 25% (CA)5.5%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (XBRA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XBRA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XBRA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XBRA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: XBRA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/02 10:09종가2025/09/04 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Xebra Brands Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (CA$3.79m market cap, or US$2.71m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
공시 • Jan 22Xebra Brands Ltd. announced that it expects to receive CAD 0.15 million in fundingXebra Brands Ltd. announced a non-brokered private placement that it will issue up to 3,000,000 units of the Company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 150,000 on January 22, 2025. Each Unit will consist of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.10 per Warrant Share at any time for a period of twenty-four months following the closing of the Offering. It is expected that the closing of the Offering will be on or about January 30, 2025, or such other date or dates that company may determine. The offering is subject to the receipt of all regulatory approvals, including the approval of the Canadian Securities Exchange. Certain directors and officers of the Company are expected to participate in the Offering.
New Risk • Jan 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Market cap is less than US$10m (CA$3.21m market cap, or US$2.24m).
공시 • Jul 09Xebra Brands Successfully Completes First Manufacturing Run for Elements Brand Ahead of Growing Demand in MexicoXebra Brands Ltd. announced the successful completion of its first manufacturing run of its highly anticipated Elements line. This milestone represents a significant next step forward in Xebra Brands' commercialization efforts as the company prepares for initial distribution efforts in Mexico. The authorization for the importation, launch, and sale of the Elements Full Spectrum CBD Tinctures were granted to Elements Bioscience SAPI de C.V, a fully owned subsidiary of Xebra Brands Ltd, by Mexican regulatory authorities (COFEPRIS), and are expected to be sold in wellness and supplement stores, pharmacies and other retail channels which have accelerated their demand for new products.
공시 • Apr 17Xebra Brands Ltd. Receives Second CBD Product Approval by COFEPRISXebra Brands Ltd. announced that it has received approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its second CBD product authorization to be sold in Mexico. This latest approval marks another milestone for Xebra Brands and highlights the Company's commitment to providing high-quality CBD products to consumers in Mexico. Building on the success of its first product approval in Mexico, Xebra Brands has obtained authorization for the transportation, launch, and sale of an additional 250mg Tincture, expanding its product offerings to meet the growing demand for premium CBD options in the region. Similar to its previously approved Tangerine Flavor CBD Tincture, this new product reflects Xebra's dedication to innovation, quality, and compliance within the CBD industry. Xebra Brands' 250mg Tincture is formulated with the same dedication to quality and purity as its previous offerings. Crafted with premium CBD extract, each batch of tincture undergoes thorough testing by third-party laboratories to ensure potency and consistency. This commitment to quality ensures that consumers in Mexico have access to trusted and reliable CBD products. With the approval of its second product by COFEPRIS, Xebra Brands reaffirms its position as a leader in the Mexican CBD industry. The company remains dedicated to meeting the evolving needs of consumers and providing natural wellness solutions that promote stress relief, relaxation, and overall well-being.
공시 • Apr 05Xebra Brands Ltd. Submits Third Product Submission to Cofepris, Expanding Elements Brand Cbd LineupXebra Brands Ltd. announced the submission of its third product application for approval to COFEPRIS (Federal Commission for Protection Against Sanitary Risk) in Mexico for domestic production. This latest submission underscores Xebra's commitment to delivering high-quality CBD products to consumers across the country in a variety of formats. The newest addition to Xebra's Elements brand is a topical lotion meticulously crafted to provide targeted relief and nourishment for the skin, infused with premium CBD extract. Designed with precision and care, this topical lotion offers consumers a luxurious skincare experience backed by the trusted Elements brand. With the submission of the Elements Topical Lotion, Xebra now covers three major product categories in the Mexico CBD market, including topicals, tinctures, and capsules. The Company intends to continue applying for new product offerings to domestically produce products and expand into additional categories to meet the evolving needs of its consumers. Once approved by COFEPRIS, the Elements Topical Lotion will be available for purchase nationwide, providing consumers with a trusted, domestically produced solution for their skincare needs.
공시 • Mar 08Xebra Brands Ltd. announced that it has received CAD 1 million in fundingOn March 7, 2024, Xebra Brands Ltd. closed the transaction. All of the units sold under the offering were purchased by David Ross Macias Diaz under a strategic investment agreement. Following the closing of the offering, David Ross Macias Diaz holds 18.04% and 30.56% of the common shares of the Company on a non-diluted basis and partially diluted basis, respectively. The offering is subject to the final acceptance of the CSE.
공시 • Feb 03+ 1 more updateXebra Brands Ltd. Announces Management ChangesXebra Brands Ltd. announced a business transformation plan that will shift the Company's resources away from Canadian cannabis beverages to focus on the development and commercialization of the authorizations to manufacture cannabis products in Mexico. As part of the implementation of the Business Transformation Plan, newly appointed board member David Ross Macias Diaz has committed to an investment into the Company. Business Transformation Plan includes: Transforming the business strategy into a Mexico first model focused on generating revenues via the cannabis authorizations granted to Xebra in 2023 through partnership opportunities, listing of own products and possible M&A transactions of companies within Mexico; Scaling down the capital-intensive operations of the Company's Canadian Cannabis Beverages business; Appointing Rodrigo Gallardo as Interim-CEO to implement the Business Transformation Plan; Streamlining current corporate and operational staff to minimize cash expenditures; Realignment of current board seats from with eight (8) members to four (4) members; Revised Business Strategy. Under the Business Transformation Plan, the Company's core focus will be on commercializing the authorizations granted to Xebra an outright first-mover-advantage in Mexico, allowing Xebra and its partners to import and acquire cannabis seeds, cultivate and harvest cannabis, process and produce cannabis, and sell cannabis products both domestically and through export.
Board Change • Nov 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Erick Ponce was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 21Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023.
공시 • Feb 17Xebra Brands Ltd. announced that it expects to receive CAD 0.6 million in fundingXebra Brands Ltd. announced a non-brokered private placement of up to 8,000,000 units at a price of CAD 0.075 per unit for gross proceeds of up to CAD 600,000 on February 15, 2023. Each unit consists of one common share and one half of one warrant. Each whole warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 per share at any time within 18 months after closing. All securities to be issued in the transaction will be subject to a 4 month and one day hold period. The transaction is subject to receipt of all required regulatory and CSE approvals. The transaction is expected to close on or around March 1, 2023. The company may pay finders' fees in cash or securities, or a combination of both, as permitted by the policies of the CSE.
Board Change • Feb 07Less than half of directors are independentFollowing Director Keith Dolo's arrival on 01 February 2023, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Feb 04Xebra Brands Ltd. Appoints Keith Dolo to the Board of DirectorsXebra Brands Ltd. announced that Mr. Keith Dolo has been appointed to Xebra's Board of Directors. Keith is a seasoned cannabis executive and was formerly the Founder and CEO Sproutly Canada one of Canada's early Licensed Producers. He is a partner with venture capital firms Greenbridge Capital and Nautilus Capital, as well the Co-Founder of Maverick Brands which is a growth agency & accelerator that invests in, supports, and scales high growth brands across many different industries including the Cannabis and beverage industries. Keith was previously a VP at Robert Half International for over a decade.
공시 • Jan 27+ 1 more updateXebra Announces Management ChangesXebra Brands Ltd. announced board and management changes. Robert Giustra has resigned as Chairman and Director in order to focus on his mining ventures. Mr. Giustra will remain an advisor to Xebra. Mr. Giustra is the founder of Xebra Brands; under his leadership, Xebra obtained an irrevocable injunction by the Mexican Supreme Court and created Xebra's unique beverage brands and trademarks. Over the last year Mr. Giustra transitioned the incoming CEO, and oversaw the Canadian launch of Xebra's highly successful THC and CBN infused lemonade Vicious Citrus. Daniela Freitas, Corporate Secretary have also resigned with Mr. Giustra to focus on the mining sector; Rodrigo Gallardo, Xebra's President, has been appointed CFO and Corporate Secretary on an interim basis.
공시 • Dec 21Xebra Brands Ltd. Announces District Court Orders Mexican FDA to Grant CannabisXebra Brands Ltd. announce, that further to its press release of December 8, 2022, a District Court judge has ruled in favor of Xebra Mexico. On December 8, 2022, Xebra announced that the Mexican Health Regulatory Agency, had formally notified Xebra's Mexican subsidiary, Desart MX, SA de CV, with a resolution in which it claimed to have complied with the Supreme Court mandate to grant Xebra cannabis authorizations. Xebra however indicated that in its opinion, and in the opinion of its legal advisors, the resolution issued by the COFEPRIS did not fulfill the mandate of the Supreme Court. A District Court judge has now reviewed the COFEPRIS resolution and ruled in favor of Xebra Mexico, outright rejecting its scope and language as materially insufficient and upholding Xebra's irrefutable legal rights granted by the Supreme Court. Thus, the judge ordered the COFEPRIS to issue the full and proper authorizations within 3 business days. Due to many Mexican government offices closing during the holiday season, Xebra anticipates the process of issuing the authorizations to continue into January 2023. Furthermore, since these cannabis authorizations are without legal precedent in Mexico, guidance on approximate timing cannot be relied upon, and additional delays can be reasonably expected. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation, processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.
공시 • Nov 18Xebra Brands Ltd. Provides Update on the Issuance of its Mexican Cannabis AuthorizationsXebra Brands Ltd. provides an update on the issuance of its Mexican cannabis authorizations. Xebra previously announced that it expected the issuance of cannabis authorizations to its Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico") in October. The Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), has been officially ordered by the courts to grant the authorization. Since these are the first cannabis authorization in Mexico related to seed importation, cultivation, processing, and manufacturing; they are without legal precedent, hence the COFEPRIS has requested, and has been granted, extensions by the courts to issue the authorizations. The most recent extension expires in approximately two (2) weeks. Xebra and the COFEPRIS are working diligently with the aim of effecting the issuance of the authorizations as soon as possible. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation and processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Aug 25Xebra's Vicious Citrus Cannabis Infused Lemonade Now SellingXebra Brands Ltd. announced that its Vicious Citrus brand of cannabis-infused lemonades is now officially retailing in Canada and available for purchase in the province of Ontario, with more provinces to follow in the coming days and weeks. Vicious Citrus is a non-carbonated THC infused lemonade beverage, with a tangy citrus flavour and a 5:1 THC /CBN ratio. With the maximum amount of psychoactive cannabinoids allowed in any Canadian listed beverage, Vicious Citrus combines 10mg of THC with 2mg of CBN (Cannabinol) and is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America.
Board Change • Aug 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jul 07Xebra Brands Ltd. Launches Vicious Citrus THC/CBN LemonadeXebra Brands Ltd. announced the successful completion of the first commercial production run of its Vicious Citrus cannabis infused lemonade. Availability is anticipated this summer in multiple provinces across Canada, including in Ontario, which has made an initial purchase order of 10,500 units for late July delivery; more than 1,100 retail cannabis store licences have been issued in Ontario, making it by far the most lucrative cannabis market in Canada. Xebra has engaged a national cannabis sales & marketing agency to introduce and support the growth of Vicious Citrus Lemonade to Canadian cannabis retailers. Xebra Launches Vicious Citrus THC/CBN Lemonade (CNW Group/Xebra Brands Ltd.) Xebra expects to launch additional Vicious Citrus cannabis infused beverages into the Canadian market later this year and into 2023. In addition, Xebra is evaluating opportunities to introduce Vicious Citrus andother Cannabis infused beverage brands into other countries.
공시 • Jun 25Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 20+ 1 more updateXebra Brands Ltd. Appoints Jay Garnett as Chief Executive OfficerXebra Brands Ltd. announced that Mr. Jay Garnett has been appointed Chief Executive Officer. Mr. Garnett, is a serial entrepreneur and corporate executive with many years of success in founding and leading consumer-packaged-goods and beverage companies in Canada and the United States.
공시 • Apr 13Xebra Brands Announces its Vicious Citrous Cannabis Infused LemonadXebra Brands Ltd. announced that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada. Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol). Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America.
공시 • Apr 12Xebra Brands Ltd. announced that it has received CAD 1.8 million in fundingOn April 11, 2022, Xebra Brands Ltd. closed the transaction. The company has received total CAD 1,800,000 through issuance of 15,000,000 units at an issue price of CAD 0.12 per unit. The transaction is oversubscribed. An aggregate of 257,063 shares, 504,560 warrants and CAD 60,547 is paid in finder's fees. The securities issued in the Private Placement are subject to a hold period expiring on August 9, 2022.
공시 • Apr 01Xebra Brands Ltd. Successfully Cultivates and Harvests First Cannabis Crop in the NetherlandsXebra Brands Ltd. announced that it has successfully cultivated and harvested its first cannabis crop in the Netherlands. Samples of the crop were collected by the Dutch government's Bureau of Medicinal Cannabis, March 25, 2022. The crop consisted of high THC ±22% cannabis flower, and flower with balanced THC ±6% and CBD± 8%. As 1 of only 5 companies to be selected by the Dutch government to participate in the medicinal cannabis cultivation pilot trial, Xebra is endeavoring to be awarded 1 of 2 licenses, providing government guaranteed revenues for each company of a minimum of approximately $80 million (€70.5 million), to supply all pharma-grade cannabis to be sold though pharmacies in the Netherlands. The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters. The deadline for the first crop was March 29, 2022 which has now been satisfied. The deadline for submission of the second crop is September 19, 2022, and March 6, 2023, for the third and final crop. A detailed business plan must also be provided to Dutch authorities by November 14, 2022. The announcement of provisional award decision by the Dutch government is scheduled for April 3, 2023, with commencement of a Framework Agreement for commercial operations planned for May 1, 2023. Cultivation in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks.
공시 • Mar 04Xebra Brands Ltd. Readies for Launch of Its Unique and Pioneering Cannabis Infused Lemonade in CanadaXebra Brands Ltd. reported on its progress towards having its first cannabis beverage product, Vicious Citrus Lemonade available for sale in Canada. The Xebra team has been actively targeting the three major provinces of Alberta, British Columbia and Ontario with its differentiated product offering. Vicious Citrus Lemonade, combines 10mg of THC with 2mg of CBN (Cannabinol) per serving for an entourage experience that cannot be found in most cannabis products in Canada. To Xebra's knowledge, Vicious Citrus is one of only very few beverages in Canada containing CBN. CBN is a unique cannabinoid that is booming in interest across North America. Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have growing excitement about for its adult use effects and potential medicinal benefits. In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone human testing. The human testing was carried-out with the approval of Health Canada.
공시 • Feb 26Xebra Brands Ltd. announced that it expects to receive CAD 1.2 million in fundingXebra Brands Ltd. announced a non-brokered private placement of up to 10,000,000 units at an issue price of CAD 0.12 per unit for gross proceeds of up to CAD 1,200,000 on February 25, 2022. Each unit is comprised of one common share, and a half warrant. Each full warrant entitles the holder, on exercise, to purchase one share at a price of CAD 0.25, for a period of 12 months from the date of issue. The company may pay finder's fees of 7% in cash or shares. The transaction is subject to approval from Canadian Securities Exchange.
공시 • Nov 24Xebra Brands Ltd. announced that it has received CAD 1.34 million in fundingOn November 23, 2021, Xebra Brands Ltd. closed the transaction.